Markets:

Overview

News

Currencies

International

Treasuries

Sanofi - American Depositary Shares (NQ:SNY)

43.49 -0.05 (-0.11%)

Streaming Delayed Price Updated: 1:25 PM EDT, May 19, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Sanofi - American Depositary Shares

< Previous 1 2

...

23 24 25 26 27 28 29 30 31

...

41 42 Next >

Regeneron Pharma Outplays Fourth-Quarter Decline, But Sanofi Stock Topples ↗

February 03, 2023

Regeneron beat forecasts despite wide declines. But Sanofi fell on its mixed report.

Via Investor's Business Daily

Nasdaq Futures Deflate As Apple Leads Tech Disappointments: Traders Look To Jobs Data For Mitigating Impact ↗

February 03, 2023

Trading in the U.S. index futures suggests stocks may end a solidly positive week on a negative note. That said, the data-dependency of the Fed places the onus of providing trading cues to each...

Via Benzinga

Sanofi Expects Moderate 2023 Profit Growth On Dupixent Demand, But Dampened By Aubagio Generics Competition ↗

February 03, 2023

Via Benzinga

Alphabet, Apple And 3 Stocks To Watch Heading Into Friday ↗

February 03, 2023

With Nasdaq stock futures trading lower this morning on Friday, some of the stocks that may grab investor focus today are as follows:

Via Benzinga

Fear & Greed Index Remains In 'Greed' Zone As Nasdaq Record Sharp Gains For Fourth Straight Week ↗

February 03, 2023

The CNN Money Fear and Greed index showed some decline in overall sentiment among US investors. US stocks closed mostly higher on Thursday, with the tech-laden Nasdaq index leading the rally. Investors...

Via Benzinga

Earnings Outlook For Sanofi ↗

February 02, 2023

Via Benzinga

Hopeful Golden Cross Forms On Sanofi's Chart ↗

January 26, 2023

Via Benzinga

What Does Sanofi's Debt Look Like? ↗

January 06, 2023

Over the past three months, shares of Sanofi Inc. (NASDAQ:SNY) increased by 20.92%. Before having a look at the importance of debt, let's look at how much debt Sanofi has.

Via Benzinga

February PDUFA Catalysts Biotech Investors Must Know: Sanofi's Bleeding Disorder Drug, Regeneron's Twin Eylea Label Expansions, 3 Delayed Approvals And More ↗

January 31, 2023

The year has started well for biopharma companies on the regulatory front, as most decisions handed out during January were positive. The Food and Drug Administration has already cleared four new...

Via Benzinga

Sanofi Layoffs 2023: What to Know About the Latest SNY Job Cuts ↗

January 31, 2023

One French pharmaceutical producer is implementing job cuts. Here's what investors need to know about the Sanofi layoffs.

Via InvestorPlace

Sanofi Might Pull Down Shutters For Two Vaccine Plants In India ↗

January 30, 2023

After Sanofi SA (NASDAQ: SNY) failed to secure a UNICEF contract, the company is weighing closing operations at two of its vaccine-making facilities in Hyderabad, India, and plans to let go of all...

Via Benzinga

Europe Approves Regeneron-Sanofi's Dupixent For Expanded Use In Eosinophilic Esophagitis ↗

January 30, 2023

Via Benzinga

Sanofi Forecasts Foreign Exchange, Record Flu Vaccine Sales To Boost Q4 Earnings ↗

January 04, 2023

Via Benzinga

Dupixent® (dupilumab) Approved by European Commission as the First and Only Targeted Medicine Indicated for Eosinophilic Esophagitis

January 30, 2023

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

Can Market Sustain Upward Momentum In Tech-Heavy Earnings Week? Apple, Amazon, AMD, Alphabet, Ford Among Key Quarterly Reports To Watch ↗

January 29, 2023

With a full week of earnings behind us, it’s time to take stock of the fourth-quarter reporting season so far. Overall, the news flow has been mixed, although tech earnings have grossly disappointed.

Via Benzinga

Could This Vaccine Become Sanofi's Latest Blockbuster? ↗

January 29, 2023

This vaccine candidate could be approved in newborns and infants later this year.

Via The Motley Fool

7 Blue-Chip Stocks to Buy as a New Bull Market Emerges ↗

January 26, 2023

Many blue-chip stocks look like a bargain right now, and these seven companies are certainly no exception.

Via InvestorPlace

Mergers and Acquisitions in 2023 Off To A Strong Start

January 26, 2023

Mergers and acquisitions are common, especially across the health sector. Here are some lesser-known buyouts and how they could fare down the road.

Via MarketBeat

Wall Street Thinks These 2 Blazing Healthcare Stocks Could Have 21% to 30% Upside in 2023 ↗

January 23, 2023

It's difficult to imagine a future where healthcare isn't in high demand.

Via The Motley Fool

Pharmaceutical Stocks Pfizer, GSK, Moderna Come Close To Cracking A Multibillion-Dollar RSV Vaccine Market ↗

January 19, 2023

After years of lab failures, the companies could crack open a multibillion-dollar market.

Via Investor's Business Daily

The Viral “Tripledemic” Opportunity ↗

January 14, 2023

Between Covid, the flu, and RSV, investors in over-the-counter consumer pharmaceutical companies might be wondering if now is a logical time to up their holdings in the companies that make cold and flu...

Via Talk Markets

Johnson & Johnson Cuts Production, Ends Contracts For Not So Successful COVID-19 Shot ↗

January 13, 2023

Johnson & Johnson (NYSE: JNJ) has significantly scaled back its efforts of manufacturing its COVID-19 vaccine after facing a fall in demand.

Via Benzinga

Sanofi Opts To Terminate Rare Disease Program With Regulus Therapeutics ↗

January 09, 2023

Via Benzinga

What This Drug News Could Mean for Sanofi Shareholders ↗

January 08, 2023

This star drug for Sanofi is one step closer to approval in the European Union for another chronic inflammatory disease.

Via The Motley Fool

5 Top Pharma Stocks of 2022 to Buy for the Long Haul ↗

January 06, 2023

The biggest drug company blockbusters bring in billions of dollars, which is one of the reasons to consider these top Pharma stocks.

Via InvestorPlace

FDA Permits Pharmacies To Distribute Abortion Pills, Tesla's Aggressive Discounting May Have Hit Gross Margins, Goldman Sachs Bullish On M&A Activity In Late 2023: Top Stories Today ↗

January 04, 2023

Reuters Goldman Sachs Bullish On M&A Deals Activity Picking Up In Late 2023

Via Benzinga

Could This Drug News Give a Lift to Eli Lilly Stock? ↗

January 01, 2023

In November, Eli Lilly received positive news from the U.S. Food and Drug Administration.

Via The Motley Fool

3 Medical Dividend Stocks That Hit the Sweet Spot ↗

December 26, 2022

These three offer high dividend yields and consistent revenue growth.

Via The Motley Fool

After Five Years Of Collaboration, Sanofi & Innate Pharma Expand Oncology Pact With Additional Programs ↗

December 19, 2022

Via Benzinga

Sanofi and Innate Pharma Expand Collaboration for Natural Killer Cell Therapeutics in Oncology

December 19, 2022

From Innate Pharma SA

Via Business Wire

< Previous 1 2

...

23 24 25 26 27 28 29 30 31

...

41 42 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.